Back

Summit Therapeutics shares rise 5.74% after AstraZeneca’s $2 billion investment

Verifying
  • Summit Therapeutics announced AstraZeneca’s investment in newly issued convertible preferred shares.
  • AstraZeneca’s $2 billion investment implies a common-stock price of $18.36 per share.
  • Summit expects closing within one week, subject to customary regulatory clearances.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.